The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.356%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Thu, 13th Jan 2022 09:10

(Alliance News) - Online fashion retailer ASOS on Thursday revealed plans to move to the London Main Market, saying it has outgrown AIM after 20 years, most of that time as its biggest listing.

ASOS, which stands for "as seen on screen", long dominated the junior market, though its current market capitalisation of GBP2.42 billion places it fifth in size on AIM. Currently the largest stock traded on AIM is Hutchmed (China) Ltd with a GBP4.18 billion market cap, followed by Abcam PLC and Fevertree Drinks PLC. The move would also put ASOS in contention to join the FTSE 250 index.

ASOS shares were up 8.2% at 2,443.00 pence in London on Thursday morning.

"ASOS directors believe that given ASOS's size and scale, now is the appropriate time to move from AIM to a premium Main Market listing," the company said, explaining it thinks the move will raise its corporate profile and recognition, and increase investment in its shares by global institutions.

ASOS said it will move its listing by the end of February. JP Morgan will act as sponsor for the Main Market admission, which won't involve any fund raise.

In conjunction with the shift, ASOS has hired Patrick Kennedy as senior independent director. Kennedy, the former chief executive of Irish betting firm Paddy Power - now Flutter Entertainment PLC - is the chair of Bank of Ireland Group PLC. He holds 23,000 ASOS shares, which are worth about GBP560,000.

ASOS also provided a trading update for the last four months of 2021.

Total revenue rose by 2.1% to GBP1.39 billion from GBP1.36 billion a year before. In constant currency, the increase was 5%. UK sales rose by 13%, while EU sales rose by 2% and US sales by 11%, both at constant currency. However, Rest of World sales fell by 15% at constant currency and by 20% at actual rates.

ASOS said that while UK sales benefited from Britons going out once again, the fourth wave of Covid-19 limited this in Europe. In the US, ASOS note significant port congestion and supply chain disruption, restricting its ability to fulfil orders. ROW sales also were hurt by "the continued impact of extended delivery propositions".

Gross margin narrowed by 400 basis points to 43.0%, as expected, ASOS said, due to clearance activity. The product returns rate has normalised in line with expectations.

ASOS said that, despite uncertainty related to the Omicron variant of Covid-19, its full-year guidance remains unchanged at 10% to 15% revenue growth and adjusted pretax profit of GBP110 million to GBP140 million. In the financial year that ended August 31, 2021, ASOS recorded GBP3.91 billion in revenue, up from GBP3.26 billion the year before, with adjusted pretax profit of GBP193.6 million, up from GBP142.1 million.

"Our listing on AIM for the past 20 years has been an important part of ASOS's development, but the time is now right to move to the Main Market as we focus on delivering our medium-term guidance and longer-term growth ambitions," said Chief Operating Officer Mat Dunn.

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 13:47

Hutchmed China completes enrolment for solveplenib clinical trial

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.

Read more
3 Jan 2023 10:28

Hutchmed completes patient enrolment for ITP clinical trial in China

(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

Read more
19 Dec 2022 19:29

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Nov 2022 11:30

Hutchmed refocuses strategy away from early-stage studies

(Sharecast News) - Hutchmed China updated the market on its strategy on Tuesday, following an "in-depth evaluation" of the business.

Read more
15 Nov 2022 10:52

Hutchmed China to shift strategy toward advanced assets in pipeline

(Alliance News) - Hutchmed (China) Ltd announced on Tuesday it will shift focus towards its most advanced assets from its internal developed pipeline, following an evaluation of the business.

Read more
14 Nov 2022 16:55

LONDON MARKET CLOSE: Europe ends higher but New York struggles

(Alliance News) - European equities surrendered some afternoon gains but made a bright start to the week on Monday, shaking off hawkish noise from the US Federal Reserve, while investors waited with bated breath for the outcome of talks between the leaders of the world's two leading economies.

Read more
14 Nov 2022 14:20

IN BRIEF: Hutchmed sees positive results for gastric cancer drug

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. Explains the drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase-three study in 703 patients, which the firm says is "clinically meaningful". Fruquintinib also shows a "statistically significant improvement" in secondary endpoints including objective response rate, disease control rate, and improved duration of response, Hutchmed adds. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

Read more
14 Nov 2022 10:27

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
14 Nov 2022 09:40

Hutchmed reports positive results from recent fruquintinib study

(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma on Monday.

Read more
27 Oct 2022 14:27

IN BRIEF: Hutchmed begins phase II/III trial of fruquintinib

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins randomised, open-label, active-controlled phase II/III trial of fruquintinib combination with sintilimab in China. The trial will explore the combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma - the most common type of kidney cancer. The first patient in China received the dose on Thursday, it says.

Read more
10 Oct 2022 10:24

Hutchmed begins sovleplenib trial for anaemia treatment in China

(Alliance News) - Hutchmed China Ltd on Monday said it has begun a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune haemolytic anaemia in China.

Read more
8 Sep 2022 11:02

Hutchmed posts positive results for CRC cancer treatment

(Alliance News) - Hutchmed China Ltd on Thursday said that its fruquintinib treatment reduced risk of death by 34% in metastatic colorectal cancer patients.

Read more
9 Aug 2022 10:04

Hutchmed notes dosing of first participant in IMG-004 study

(Alliance News) - Hutchmed China Ltd on Tuesday said it has dosed its first participant in its global phase one trial of IMG-004.

Read more
8 Aug 2022 12:42

Hutchmed upbeat on latest study results for colorectal cancer treatment

(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib' met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer (CRC).

Read more
8 Aug 2022 11:32

UPDATE: Hutchmed, AstraZeneca move lung cancer drug to phase 3 trial

(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.